Loading
Nanoparticle-based Drug Delivery / Cancer, Hypoxia, and Metabolism / Nanoplatforms for Cancer Theranostics · Journal article
Nature Communications · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study describing the design and function of a multi-drug nanoparticle platform (GS@DFP) targeting glioblastoma mitochondria and astrocyte-cancer crosstalk in cell and animal models. The work is exploratory and hypothesis-generating; it establishes a potential therapeutic approach but provides no human efficacy or safety data, and no direct clinical comparison.
Preclinical mechanistic study (cell culture and animal model). Glioblastoma cells and tumor-bearing animals; astrocytes in co-culture models.. Intervention: GS@DFP nanoplatform co-loaded with S-Gboxin and Galunisertib, targeting GBM mitochondria and astrocyte-cancer mitochondrial transfer..
GS@DFP nanoplatform crosses blood-brain barrier via Glut1-mediated DHA transport S-Gboxin inhibits mitochondrial complex V and depletes ATP in GBM cells Galunisertib downregulates TGF-β/SMAD-driven TSP-1 expression, suppressing tumor microtube formation and reducing astrocyte-to-GBM mitochondrial transfer
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work presents a preclinical strategy and requires substantial further development before clinical translation. Clinicians should not consider this evidence for treatment decisions; it serves as a research foundation for future development.
Preclinical proof-of-concept study demonstrating a novel nanoplatform mechanism in cell and animal models, without human efficacy data or direct comparison to standard therapy.
As stated by the source record.
This work presents a preclinical strategy and requires substantial further development before clinical translation. Clinicians should not consider this evidence for treatment decisions; it serves as a research foundation for future development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Glioblastoma (GBM) remains incurable and exhibits exceptionally high metabolic demands, driving the evolution of hyperactive mitochondrial systems within tumors. In parallel, mitochondrial transfer from astrocytes to cancer cells fuels metabolic reprogramming and enhances GBM tumorigenicity. These malignant traits markedly constrain therapeutic efficacy and patient survival. Herein, we report a dehydroascorbic acid (DHA)-functionalized, ROS-responsive, ferrocene-integrated polymer nanoplatform (GS@DFP) co-loaded with S-Gboxin and Galunisertib, simultaneously targeting GBM mitochondria and mitochondrial transfer in astrocyte-cancer cell crosstalk. After crossing the blood-brain barrier (BBB) through Glut1-mediated transport enabled by DHA, GS@DFP responds to elevated intracellular reactive oxygen species (ROS) levels in GBM to trigger payload release and initiate Fenton reactions. S-Gboxin inhibits mitochondrial complex V and depletes ATP, whereas Galunisertib downregulates TGF-β/SMAD-driven thrombospondin-1 (TSP-1) expression, suppressing tumor microtube (MT) formation and thereby reducing astrocyte-to-GBM mitochondrial transfer. Notably, TGF-β inhibition also reprograms the immunosuppressive tumor microenvironment (TME). This work establishes a multifunctional nanoplatform that targets mitochondrial vulnerabilities and intercellular crosstalk, offering a translatable strategy for enhancing GBM therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.